Compare Dyne Therapeutics Inc. Common Stock (DYN) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.04 (market cap $2.81B), while JPMorgan Diversified Return International Eqty ETF trades at $73 (market cap $380.28M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 7.4× JPMorgan Diversified Return International Eqty ETF's market cap, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and JPMorgan Diversified Return International Eqty ETF for 121 Days on average.
| DYN | JPIN | |
|---|---|---|
Market Cap | $2.81B | $380.28M |
Volume | 2,195,902 | 4,689 |
Sector | Health | — |
52-Week High | $26.78 | $77.80 |
52-Week Low | $14.60 | $65.86 |
Typical Hold Time | 0 Days | 121 Days |
Enterprise Value | $2.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
JPIN trades at $73.52, up 0.65% with bearish technical signals dominating. The ETF shows oversold RSI readings but faces strong selling pressure across moving averages and ADX indicators. Support and resistance cluster tightly around $73-74, suggesting potential for near-term volatility. Recent dividend announcement for September 2026 provides future income potential.
The ETF's outlook remains challenged by bearish momentum despite oversold conditions. Investment opportunity exists for value investors seeking international equity exposure, though risks include continued technical weakness and market volatility. The concentrated price action around current levels indicates potential breakout or breakdown scenario ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
